09 Nov Tiansen Li joins Odylia Advisory Board
Tiansen Li joins the Board of Advisors for Odylia Therapeutics
Atlanta, GA November 9, 2020 – Tiansen Li, PhD, joins the Board of Advisors for Odylia Therapeutics. Tiansen is a senior investigator at the National Eye Institute at the NIH. He received his PhD from Purdue University in 1991 and completed his post-doctoral training at the Visual Sciences Center, University of Chicago. In 1992, he joined the Department of Ophthalmology, Harvard Medical School at the Massachusetts Eye and Ear Infirmary and rose through the ranks to Associate Professor of Ophthalmology (Neuroscience). He moved to NEI in the fall of 2009.
As a member of Odylia’s Advisory Board, Dr. Li is a resource for our scientific team as prospective therapies are evaluated. “Dr Li brings new insight into disease pathobiology and expands our knowledgebase of promising gene therapies,” said Ashley Winslow, Chief Scientific Officer.
A major area of Dr. Li’s research is to investigate the functions of genes now known to be involved in photoreceptor degeneration, including retinitis pigmentosa, Usher Syndrome, and a more severe form of photoreceptor degeneration known as Leber Congenital Amaurosis (LCA). His group conducts research using genetic model systems as well as induced stem cell-derived organoids. He is also actively engaged in therapeutic studies, primarily replacement gene therapy, for retinal degenerations.
“We are very excited to have Tainsen join the Odylia Advisory Board,” said Scott Dorfman, Odylia Therapeutics’ CEO. “His experience in gene therapy is an asset to Odylia and will further our mission of advancing treatments for rare diseases.”